Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | KDM5A | P29375 | 4/20 | 0.33 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.32 |
| ▸ | XDH | P47989 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21363537 | 0.77 | IMPDH2 (0.36) | IMPDH2KDM4EALDH1A1GAAGLA | |
| SCHEMBL26156196 | 0.77 | IMPDH2 (0.36) | IMPDH2KDM4EALDH1A1GAAGLA | |
| SCHEMBL22477748 | 0.73 | — | — | |
| SCHEMBL27254195 | 0.67 | ALDH1A1 (0.37) | KDM4EALDH1A1GAAGLATDP1 | |
| SCHEMBL20155367 | 0.66 | CREBBP (0.34) | KDM4EALDH1A1PDE1C | |
| SCHEMBL21367817 | 0.65 | ADORA2A (0.38) | ALDH1A1 | |
| SCHEMBL4351354 | 0.64 | KDM5A (0.36) | KDM4EALDH1A1GAAGLAKDM5A | |
| SCHEMBL25291001 | 0.63 | CDK2 (0.34) | KDM4EALDH1A1KDM5A | |
| SCHEMBL55228 | 0.63 | KDM4E (0.44) | KDM4EALDH1A1XDH | |
| SCHEMBL12689106 | 0.63 | CDK2 (0.34) | KDM4EALDH1A1KDM5APDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10710994-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190284179-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284179-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | TRPA1, TRPV1, TRPV3 | IMPDH2 3542/4885KDM4E 4048/4885ALDH1A1 721/4885 |
| US-10710994-B2 | Oxadiazole transient receptor potential channel inhibitors | TRPA1, TRPV1, TRPV3 | IMPDH2 3542/4885KDM4E 4048/4885ALDH1A1 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.